IN 1922, Stevens and Johnson described a syndrome in children that is characterized by febrile erosive stomatitis, severe ocular involvement, and disseminated cutaneous eruptive macules sometimes with a necrotic center. 1 In 1956, Lyell described toxic epidermal necrolysis (TEN) referring to patients with extensive loss of epidermis due to necrosis and a scalded-looking skin. 2 Although precise diagnostic boundaries between the two disorders have not been established, patients with less than 10% of epidermal detachment are classified as Stevens-Johnson syndrome (SJS), whereas those with more than 30% of total body surface area involvement are classified as TEN. 3, 4 Not infrequently, patients may present with a clinical picture of SJS that evolves to one of TEN within few days. 3, 5 TEN mimics burn injuries in its clinical presentation and behavior. It is characterized by large areas of skin desquamation and sloughing of the epidermal layers uncovering the underlying dermis that can be potentially fatal. 6 When extensive epidermal loss occurs, transfer of the patient to a surgical intensive care facility or even to a burn unit becomes a necessity. 3, [7] [8] [9] The incidence of TEN is 1 per million, 10 occurring mainly in adults with a mortality rate ranging between 11% and 70%. 5, 6, 8, 11 It is characterized clinically by a febrile prodrome simulating an upper respiratory tract infection 11 followed by a diffuse morbilliform eruption or confluent erythema 12 that progresses into the acute phase of persistent fever, mucous membrane involvement, and generalized epidermal sloughing. 7, 8, 10, 11 Total epidermal loss within 24 hours is not infrequent. 11 Scepticemia is the most frequent cause of death in patients with TEN and is usually due to staphylococcus aureus or pseudomonas. 1, 7, 9, 10, 13 The condition may have numerous and diverse etiologies; 5, 7, 8, [14] [15] [16] however, the overwhelming majority of cases are drug induced. 5, 7, 10, 11, 13, [17] [18] [19] [20] [21] One hundred different drugs have been implicated with this syndrome, 22 the most notorious of which are none steroidal anti-inflammatory drugs, anticonvulsants, and antibiotics such as penicillins and sulfonamides. 4, 7, 8, 10, 11, 14 Although the immunologic pattern of cutaneous and mucocutaneous lesions suggests a cell-mediated cytotoxic reaction against epidermal cells rather than direct toxic effect, 19, [23] [24] [25] it is now clear that both immunologic and nonimmunologic mechanisms may be incriminated. 6, 17 The treatment of cutaneous drug reactions is very much individualized; 18 however, it rests essentially on immediate diagnosis and recognition of the disease process, accurate history, thorough physical examination, prompt discontinuation of the offending drug, and supportive care. 18, 26 Topical wound management remains an essential factor in the treatment of burnlike syndromes and is a main determining parameter for morbidity and mortality.
In a previous report, 5 we stressed, as did many others, 7 the importance of managing patients with TEN in specialized burn units. We have also outlined the rationale for topical wound care in order to achieve speedy re-epithelialization while avoiding damage to the denuded dermis as well as to the newly regenerating stratified epithelium. As the value of moist environment in wound healing is being fully appreciated, 27 we have been experimenting the effect of a newly introduced ointment, the Moist Exposed Burn Ointment (MEBO) (Julphar; Gulf Pharmaceutical industries, Ras El-Khaymah, United Arab of Emirutes), on wound healing. [28] [29] [30] [31] [32] We report on the use of this moisture-retentive ointment in the management of a case of TEN.
Case Report
In January 1999, a 50-year-old known hypertensive male patient was admitted 2 days after noticing the first signs and symptoms to Dagestani Hospital (Jeddah, Kingdom of Saudi Arabia) with the diagnosis of toxic epidermal necrolysis involving 90% of the total body surface area. On admission, the patient's vital signs were as follows: temperature 36.81C, pulse 88/m, and blood pressure 120/90 mm Hg. Laboratory tests on admission were within normal limits with a hemoglobin of 14.3 mg/mL. By history, the first cutaneous lesions appeared 5 hours after intake of sulfonamide tablets (two tablets), which seem to be the etiologic agent that is responsible for the disease process.
The patient was managed as a major burn. Fluid requirements in the first 24 hours were calculated and administered according to the Brook-Army formula maintaining adequate hydration. Subsequently, adjustments in fluid perfusions were made taking into consideration the urinary output. On admission, the cutaneous bullous lesions were evacuated and cleaned with normal saline and betadine solution. On the second day of admission, MEBO was applied together with a secondary overlying protective dressing. The dressing was maintained without disruption for 4 days. Ointment application with overlying dressing at a 4-day interval was repeated three times, after which the open method of ointment application was adopted and continued for a total of 4 weeks until complete reepithelialization was achieved. The patient had an uneventful course with no complications. At the end of the healing process, pigmentation changes were noticeable all over the healed skin; however, there were no signs of scar hypertrophy (Figure 1 ).
Discussion
Although it is now generally agreed that patients presenting with the clinical picture of SJS and TEN are better managed in a specialized burn unit, some differences do exist between the ''burn-like'' syndromes and the burn injury itself that deserve a better understanding, as these may have great implications on the therapeutic modalities that patients ought to receive. Severe thermal or chemical burns produce damage to both the epidermal and dermal layers relative to the intensity of the injurious agent as well as to the duration of exposure. In SJS and TEN patients, there is a full-thickness epidermal sloughing with the cleavage plane at the epidermal-dermal junction. 5, 7, 9, 26, 33 Although a moderate degree of edema is present in the papillary dermis, 26 the reticular dermis is completely normal 34 with total preservation of collagen and reticular fibers. 7 Similar to what is observed in second-degree burns, regeneration of the epidermis proceeds from the epithelial remnants of the sweat glands and the hair follicles; 35 however, it is worth noting that because in SJS and TEN the dermis is preserved and is completely viable unlike seconddegree burns, less scarring is to be expected after reepithelialization. 5, 9 It is hence even more crucial to protect the preserved dermis during the healing phase from infection, desiccation, and subsequent injury 7, 36 by thoughtful and carefully executed dressing changes, providing the necessary moisture for optimal speedy re-epithelialization. Logically surgical tangential excision should be absolutely contraindicated in TEN, and biologic dressings and skin substitutes must be favored 7,9,37,38 over classic burn dressings that do not provide a moist environment and have an inherent mechanical debriding capacity that damages the regenerating keratinocytes. 5 Although burn injuries have traditionally been considered as special types of wounds requiring specialized management protocols, healing of burn or burn-like wounds does not differ in any way from healing of any other type of wound. It is only logical that general principles of wound healing apply to such wounds as well. Widely used topical antimicrobial agents for local burn wound management have been developed mainly in order to reduce the incidence of burn wound sepsis and its associated morbidity and mortality. This goal has been largely attained. Silver sulfadiazine cream is widely used for topical treatment of burns as well as of SJS and TEN; however, it is not moisture retentive. The secondary absorbent semiopen dressing usually applied in association with silver sulfadiazine cream is labor intensive, costly, and associated whenever changed with considerable discomfort and pain to the patient. 39 Moreover, its use should be restricted to those patients with no previous history of hypersensitivity to sulfonamides. 7, 8 It must be mentioned also that pemphigus-like eruptions have been described as early as 1942 in association with sulfadiazine therapy. 40 With topical burn wound management, little concern is made regarding conditions for optimal and speedy healing. In contrast, a reduction in burn wound sepsis results in net prolongation of healing time because of delayed eschar separation. In contrast to other topical ointments for burns, MEBO has the added advantage of addressing both issues of burn wound sepsis and burn wound healing at the same time. It acts like other ointments as an effective antibacterial agent but without the emergence of resistant strains, and at the same time, it acts like an occlusive or semiocclusive dressing, promoting rapid autolytic debridement and optimal moist wound healing. 27 Faster restoration of cutaneous barrier function with decreased transepidermal water loss demonstrated with MEBO application 31 may yet be another advantage for using the moisture retentive ointment particularly in the management of SJS and TEN. Moreover, protecting the denuded undamaged dermis for the duration of re-epithelialization enhances the chances for no or minimal scarring.
Conclusion
A case of TEN has been successfully managed with the application of a MEBO. In addition to its antibacterial effect, the ointment provides the necessary moist environment for optimal speedy healing by re-epithelialization, protects denuded yet undamaged dermis, and induces rapid cutaneous barrier function restoration. All of these positive actions on anatomical as well as on physiologic healing provided by one single agent, in addition to the practical method of application without the need for labor-intensive and cumbersome dressings except rarely, are obvious advantages for the use of MEBO over other products and agents in the management of SJS and TEN.
